| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | TAJ alpha; TAJ; TNFRSF19; TRADE; TROY;;TNFRSF19 |
| WB Predicted band size | 46 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human TNFRSF19 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于TROY抗体的3篇参考文献示例(文献信息为虚构，仅供示意参考)：
---
1. **文献名称**: *TROY monoclonal antibody inhibits glioma stem cell proliferation via blocking TNF signaling*
**作者**: Smith A, et al. (2015)
**摘要**: 该研究开发了一种靶向TROY受体(TNFRSF19)的单克隆抗体，证实其可通过抑制TNF-α/TROY信号通路，阻断胶质瘤干细胞的自我更新能力，显著降低小鼠模型中肿瘤的生长和侵袭性。
2. **文献名称**: *Targeting TROY in inflammatory bowel disease: antibody-mediated neutralization reduces intestinal inflammation*
**作者**: Zhang Y, et al. (2018)
**摘要**: 研究利用人源化TROY抗体在小鼠结肠炎模型中验证其疗效，发现抗体通过阻断TROY与配体结合，抑制NF-κB通路的激活，从而减少促炎细胞因子释放，缓解肠道炎症反应。
3. **文献名称**: *TROY antibody-drug conjugate enhances chemotherapy efficacy in triple-negative breast cancer*
**作者**: Lee J, et al. (2022)
**摘要**: 该团队设计了一种TROY抗体-药物偶联物(ADC)，靶向高表达TROY的三阴性乳腺癌细胞。临床前实验显示，该ADC可特异性递送化疗药物，显著抑制肿瘤转移并延长小鼠生存期。
---
注：以上文献为示例，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实发表的论文。
**Background of TROY Antibody**
TROY (TNF receptor-associated factor [TRAF]-interacting protein), also known as TAJ or TNFRSF19. is a member of the tumor necrosis factor receptor superfamily (TNFRSF). Initially identified in 2001. it is a type I transmembrane protein implicated in diverse biological processes, including neural development, tissue homeostasis, and cancer progression. TROY lacks a canonical death domain but interacts with TRAFs to activate downstream signaling pathways, such as NF-κB and JNK, which regulate cell survival, differentiation, and apoptosis.
In neuroscience, TROY is expressed in oligodendrocytes and neural stem cells, where it modulates myelination and neural regeneration. Its role in cancer is context-dependent: TROY can act as an oncogene or tumor suppressor, depending on the tissue type. For example, it promotes invasiveness in glioblastoma and melanoma but suppresses Wnt/β-catenin signaling in colorectal cancer.
TROY antibodies are essential tools for detecting TROY expression in research, enabling studies on its functional mechanisms and therapeutic potential. They are used in techniques like Western blotting, immunohistochemistry, and flow cytometry to investigate TROY's involvement in diseases. Recent interest focuses on targeting TROY signaling to treat aggressive cancers or enhance neural repair, though challenges remain in understanding its ligand interactions and pathway crosstalk. Overall, TROY antibodies are pivotal in unraveling the protein's dual roles in physiology and pathology.
×
